Researchers at Huntsman Cancer Institute identified potential new treatment options for people with endometrial cancer. Endometrial cancer is the most common gynecological cancer and high levels of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III INAVO120 study of the ...

Positive news for women with a common type of advanced breast cancer — hormone receptor-positive (HR+), HER2-negative (HER2-) — emerged at the 2025 American Society of Clinical Oncology (ASCO) annual ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating ...

Some breast cancers “feed” on the hormone estrogen. These are usually treated with medicines that either block estrogen’s signal (fulvestrant) or slow the cancer’s growth cycle (palbociclib). In about ...

Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone ...

Patients with growth hormone receptor deficiency, or Laron syndrome, appear to have lower than average risk factors for cardiovascular disease, according to a new study. A new study highlights ...

An interview with Dr. Harold Burstein from Dana Farber Cancer Institute in Boston, MA, chair on “Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast ...

– Phase III (INAVO120) results shows that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting – – PIK3CA mutations, ...